Intermittent administration of valacyclovir is effective for prevention of herpes zoster events in patients with multiple myeloma treated with bortezomib
10.3969/j.issn.1007-3969.2014.07.009
- VernacularTitle:间断口服伐昔洛韦预防多发性骨髓瘤患者应用硼替佐米致带状疱疹的临床观察
- Author:
Yiyun YAO
;
Yong TANG
;
Yan ZHUANG
;
Lei WANG
;
Lifang ZOU
;
Qi ZHU
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Bortezomib;
Herpes zoster;
Valacyclovir
- From:
China Oncology
2014;(7):525-528
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Herpes zoster is a common adverse event associated with the use of bortezomib. The objective of this study was to evaluate the efifcacy of different therapeutic regimens of valacyclovir prophylaxis: continuously administration and intermittent administration. Methods: We retrospectively analyzed the efficacy, side effects, expense of valacyclovir and emotional states of 31 patients with multiple myeloma who received bortezomib and valacyclovir prophylaxis. Among them, 14 patients underwent continuously administration of valacyclovir, the other 17 patients underwent intermittent administration. Continuously administration was deifned as daily oral valacyclovir 600 mg without cessation during entire period of bortezomib treatment. Intermittent administration was deifned as patients received valacyclovir at a dose of 600 mg daily during chemotherapy, while discontinue valacyclovir at the intermission time of bortezomib treatment. Results: There were no herpes zoster in patients of 2 arms. Adverse events over grade 3 associated with valacyclovir were not observed. Intermittent administration of valacyclovir showed a superiority of economic beneift. The emotional status were depended on the therapeutic effects of multiple myeloma. For those relapsed or refractory patients, continuously administration of valacyclovir might aggravate depression and anxiety. Conclusion:Intermittent administration of valacyclovir at a dose of 600 mg daily appears to be an effective prophylaxis for herpes zoster in patients receiving bortezomib.
